SCHEMBL2943833

SCHEMBL2943833

FC(F)(F)c1cccc(-c2cnc3ccc(NCc4ccncc4)nn23)c1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FYN P06241 7/20 0.71
MKNK1 Q9BUB5 2/20 0.65
PIM1 P11309 6/20 0.60
DYRK1A Q13627 5/20 0.60
DYRK2 Q92630 5/20 0.60
CCNA2 P20248 4/20 0.60
CDK2 P24941 4/20 0.60
CDK5 Q00535 4/20 0.60
CDK5R1 Q15078 4/20 0.60
DYRK1B Q9Y463 4/20 0.60
CCNT1 O60563 3/20 0.60
CDK9 P50750 3/20 0.60
NTRK1 P04629 1/20 0.58
NTRK3 Q16288 1/20 0.58
NTRK2 Q16620 1/20 0.58
KCNH2 Q12809 1/20 0.58
DYRK3 O43781 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13223355 0.90 MKNK1 (0.71) FYNMKNK1PIM1DYRK1ADYRK2
SCHEMBL2943855 0.85 PIM1 (0.82) FYNMKNK1PIM1DYRK1AKCNH2
SCHEMBL2950204 0.85 FYN (0.67) FYNMKNK1PIM1DYRK1ADYRK2
SCHEMBL2942579 0.85 NTRK1 (0.67) FYNPIM1DYRK1ADYRK2CCNA2
SCHEMBL2944601 0.84 FYN (0.76) FYNMKNK1PIM1DYRK1ADYRK2
SCHEMBL2949823 0.84 FYN (0.76) FYNMKNK1PIM1NTRK1NTRK3
SCHEMBL13234450 0.84 FYN (1.00) FYNMKNK1PIM1NTRK1NTRK3
SCHEMBL2944080 0.82 PIM1 (0.76) FYNMKNK1PIM1DYRK1ADYRK2
SCHEMBL3041871 0.82 FYN (0.88) FYNMKNK1PIM1NTRK1NTRK3
SCHEMBL13223428 0.82 FYN (0.63) FYNMKNK1PIM1DYRK1ADYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 FYN 421/4885MKNK1 144/4885PIM1 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.